Article citationsMore>>

Berron-Perez, R., Chavez-Sanchez, R., Estrada-Garcia, I., Espinosa-Padilla, S., Cortez-Gomez, R., Serrano-Miranda, E., Ondarza-Aguilera, R., Perez-Tapia, M., Pineda Olvera, B., Jimenez-Martinez, M.C., Portugues, A., Rodriguez, A., Cano, L., Pacheco, P.U., Barrientos, J., Chacon, R., Serafin, J., Mendez, P., Monges, A., Cervantes, E. and Estrada-Parra, S. (2007) Indications Usage, and Dosage of the Transfer Factor. Revista Alergia México, 54, 134–139.

has been cited by the following article:

• TITLE: The Adverse Event Profile in Patients Treated with TransferonTM (Dialyzable Leukocyte Extracts): A Preliminary Report

  AUTHORS: Toni Homberg, Violeta Sáenz, Jorge Galicia-Carreón, Iván Lara, Edgar Cervantes-Trujano, Maria C. Andaluz, Erika Vera, Oscar Pineda, Julio Ayala-Balboa, Alejandro Estrada-García, Sergio Estrada-Parra, Mayra Pérez-Tapia, Maria C. Jiménez-Martínez

  KEYWORDS: Dialyzable Leukocyte Extracts, Adverse Events, Monitoring, Drug Safety, Adjuvant Therapy, Immunoregulation, Guidelines, Transfer Factor, Pharmacovigilance

  JOURNAL NAME: Pharmacology & Pharmacy, Vol.6 No.2, February 10, 2015

  ABSTRACT: Background: Dialyzable leukocyte extracts (DLE) are heterogeneous mixtures of peptides less than 10 kDa in size that are used as immunomodulatory adjuvants in immune-mediated diseases. TransferonTM is DLE manufactured by National Polytechnic Institute (IPN), and is registered by Mexican health-regulatory authorities as an immunomodulatory drug and commercialized nationally. The proposed mechanism of action of TransferonTM is induction of a Th1 immunoregulatory response. Despite that it is widely used, to date there are no reports of adverse events related to the clinical safety of human DLE or TransferonTM. Objective: To assess the safety of TransferonTM in a large group of patients exposed to DLE as adjuvant treatment. Methods: We included in this study 3844 patients from our Clinical Immunology Service at the Unit of External Services and Clinical Research (USEIC), IPN. Analysis was performed from January 2014 to November 2014, searching for clinical adverse events in patients with immune-mediated diseases and treated with TransferonTM as an adjuvant. Results: In this work we observed clinical nonserious adverse events (AE) in 1.9% of patients treated with TransferonTM (MD 1.9, IQR 1.7 - 2.0). AE were 2.8 times more frequently observed in female than in male patients. The most common AE were headache in 15.7%, followed by rash in 11.4%, increased disease-related symptomatology in 10%, rhinorrhea in 7.1%, cough in 5.7%, and fatigue in 5.7% of patients with AE. 63% of adverse event presentation occurred from day 1 to day 4 of treatment with TransferonTM, and mean time resolution of adverse events was 14 days. In 23 cases, the therapy was stopped because of adverse events and no serious adverse events were observed in this study. Conclusion: TransferonTM induced low frequency of nonserious adverse events during adjuvant treatment. Further monitoring is advisable for different age and disease groups of patients.